Stock Analiz

CDT Equity Inc. CDT

Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026

$0.40Market cap $407552
Open the interactive analysis →

CDT Equity Inc. (CDT) is a healthcare company listed in the US with a market value of about $407552.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -1212%.

About CDT Equity

CDT Equity is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 0 of the last 4 years in our data. Its share count rose by 26580% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield26.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-1212.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal year2025202420232022
Revenue————
Net income-$39M-$18M-$535000-$5M
Free cash flow—-$10M——
EPS (diluted)$-1177.89$-61598.62$-26762.96$-39004.31
Net margin————
ROIC——-1212.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does CDT Equity pay a dividend?

Not currently.

Is CDT Equity a good stock to buy?

We do not give buy or sell advice. CDT Equity scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.